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Russ Hauser, Niels E. Skakkebaek, Ulla Hass, Jorma Toppari, Anders Juul,
Anna Maria Andersson, Andreas Kortenkamp, Jerrold J. Heindel,
and Leonardo Trasande*
Introduction: Increasing evidence suggests that endocrine-disrupting chemicals (EDCs) contribute
to male reproductive diseases and disorders.
Purpose: To estimate the incidence/prevalence of selected male reproductive disorders/diseases
and associated economic costs that can be reasonably attributed to specific EDC exposures in the
European Union (EU).
Methods: An expert panel evaluated evidence for probability of causation using the Intergovern-
mental Panel on Climate Change weight-of-evidence characterization. Exposure-response rela-
tionships and reference levels were evaluated, and biomarker data were organized from carefully
identified studies from the peer-reviewed literature to represent European exposure and approx-
imate burden of disease as it occurred in 2010. The cost-of-illness estimation utilized multiple
peer-reviewed sources.
Results: The expert panel identified low epidemiological and strong toxicological evidence for
male infertility attributable to phthalate exposure, with a 40–69% probability of causing 618 000
additional assisted reproductive technology procedures, costing €4.71 billion annually. Low epi-
demiological and strong toxicological evidence was also identified for cryptorchidism due to pre-
natal polybrominated diphenyl ether exposure, resulting in a 40–69% probability that 4615 cases
result, at a cost of €130 million (sensitivity analysis, €117–130 million). A much more modest
(0–19%) probability of causation in testicular cancer by polybrominated diphenyl etherswas iden-
tified due to very low epidemiological and weak toxicological evidence, with 6830 potential cases
annually and costs of €848 million annually (sensitivity analysis, €313–848 million). The panel
assigned 40–69%probability of lower T concentrations in 55- to 64-year-oldmendue to phthalate
exposure, with 24 800 associated deaths annually and lost economic productivity of€7.96 billion.
Conclusions: EDCs may contribute substantially to male reproductive disorders and diseases, with
nearly€15 billion annual associated costs in the EU. These estimates represent only a few EDCs for
which there were sufficient epidemiological studies and those with the highest probability of
causation. Thesepublic health costs shouldbe consideredas theEUcontemplates regulatory action
on EDCs. (J Clin Endocrinol Metab 100: 1267–1277, 2015)
During the past few decades, rates of testicular germcell cancer (TGCC) have increased among young
men all over the world, particularly among Caucasians.
The highest incidences of TGCC have been found among
Caucasians in Europe, the United States, Chile, Australia,
and New Zealand, indicating a genetic component to tes-
ticular cancer. In the United States, Caucasians are signif-
icantly more prone to develop TGCC, although the dis-
parity is decreasing (1). Denmark and Norway have
witnessed quite dramatic increases over only two gener-
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ations (2, 3), and previous “low-incidence” countries like
Finland, Italy, Spain, and Holland are now catching up
with rather substantial increases (4). In addition, on av-
erage a 25% increase in Europe can be expected by 2025,
according to the International Agency for Research in
Cancer.
Genome-wide association studies show that genetics
can only explain 20–25% of TGCC (5), suggesting a role
for environmental factors such as endocrine-disrupting
chemicals (EDCs). Studies on immigrants to Sweden from
DenmarkandFinlandhave shown that the first generation
of children carry the risk of TGCC from their home coun-
try, whereas the next generation growing up in Sweden
obtains the Swedish risk of TGCC (6), also suggesting a
role for environmental factors.Numerous biological stud-
ies are in linewith the fetal hypothesis for testicular cancer
(7, 8). The precursor cell for TGCC, the carcinoma in situ
cell, expresses embryonic markers similar to primordial
germ cells (9). Furthermore, given that the epidemic of
TGCC has occurred over a relatively short period of time
(ie, decades), it is likely that only environmental factors
can explain the trends.
There are also data to suggest that the incidence of
cryptorchidism, a strong risk factor for TGCC, is increas-
ing (10, 11), although the incidences vary (12). Phthalates,
pesticides, brominated flame retardants, diethylstilbes-
trol, and dioxins are among the synthetic chemicals that
have been identified as plausible contributors (13). Male
infertility is also common, although exact numbers are
difficult to ascertain because it must be considered a con-
dition of a couple, where the reproductive health of both
sexes plays a role (14). In Denmark, where reliable regis-
tration of all types of assisted reproduction takes place,
8% of all children are now born after assisted reproduc-
tion (http://www.fertilitetsselskab.dk). Although genetic
forms of male infertility exist, including chromosome dis-
orders, eg, Klinefelter syndrome (15) and Y microdele-
tions (16), in most cases no known etiology exists. Epide-
miological studies have explored associations of reduced
male fertility and poor semen quality withmultiple EDCs,
including phthalates, bisphenol A, and polyfluorinated
chemicals (17).
Infertility due to poor semen quality, as in cryptorchid-
ism and hypospadias, is also a risk factor for decreased
Leydig cell function with a decreased T/LH ratio (18).
There are now three large studies from the United States,
Denmark, and Finland showing serum T levels falling
among otherwise healthy men in the general population,
with some, but not all, of the results explained by increas-
ing rates of obesity (18–20). Because T has a fundamental
role for normal male physiology and health (21), these
trends raise concerns about a role for environmental en-
docrine disruptors in reduced sex steroids.
This epidemic of male reproductive problems, which
cannot be explained by genetic changes, has occurred con-
temporaneously with increasing exposures to various en-
vironmental factors through modern lifestyle. Increasing
evidence shows that such exposures include multiple
EDCs that can induce male reproductive disorders and
diseases in experimental animals similar to what we are
witnessing in humans. The EDCs causing such effects in
experimental animals include chemicals such as phtha-
lates, including dibutyl phthalate (DBP) and diethylhexyl
phthalate (DEHP); pesticides, including procymidone,
vinclozolin, linuron, and prochloraz; bisphenol A; the di-
chlorodiphenyltrichloroethane metabolite p,p’-Dichloro-
diphenyldichloroethane; and UV filters, such as octyl me-
thoxycinnamate and 4-methylbenzylidene camphor (22,
23). Concurrentwith the accumulating evidence in animal
studies, there are an increasing number of human studies
suggesting thatEDCsmaycontribute tomale reproductive
disorders and diseases (24).
The burden of male reproductive health problems is
significant, both at the individual and population level.
They are also costly. Prevention of EDC exposures has the
potential to reduce the incidence of many male reproduc-
tive disorders and diseases and their associated health care
and other social costs in the European Union (EU) (24). In
the context of the ongoing regulatory process, we there-
fore examined probability of causation for EDCs in male
reproductive disorders and quantified the potential bur-
den of disease and costs.
Materials and Methods
Overall approach
The expert panel focused on four exposure-outcome relation-
ships: 1) phthalates and infertility; 2) polybrominated diphenyl
ethers (PBDEs) and testicular cancer; 3) PBDEs and cryptorchid-
ism; and 4) phthalates and reduced serum T. The panel selected
these exposure-outcome relationships frommanyothers because
of the presence of well-conducted human and animal studies to
assess reproductive effects of these EDCs. We adhered to the
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approach described in the accompanying overarching manu-
script (92) in evaluating the strength of the epidemiological (25,
26) and toxicological literature (27) and assigning probability of
causation (28). The Supplemental Data describes exposure bio-
marker inputs used tomodel exposure in the EU and approaches
to valuing costs of testicular cancer, cryptorchidism, infertility
and the subsequent need for assisted reproductive technology
(ART), and mortality due to reductions in T, whereas subse-
quent sections of this article describe the estimation of affected
populations and attributable prevalence/incidence.
Modeling PBDE-attributable cryptorchidism
The expert panel selected a case-control study of breast milk
PBDE in relationship to cryptorchidism to extrapolate attribut-
able burden and costs (29). The population distribution of PBDE
in breast milk in the EU (10th, 25th, 50th, 75th, and 90th per-
centiles) was extrapolated from levels in serum using data from
a systematic review that identified a serum/milk ratio averaging
0.8, with a range of 0.54–0.9 (93). The mean ratio was used in
main estimates, whereas the entire range was incorporated in
sensitivity analyses. Following a request from the panel, the first
author of this case-control study calculatedodds ratios (ORs) for
cryptorchidism per natural log unit (30).We then exponentiated
them by the ratio of the estimated PBDE levels in breast milk,
assuming a reference level corresponding to the 50th percentile
in the EU. This exponentiation generated OR values in each of
the highest quantiles in the EU, which were multiplied by inci-
dence of congenital cryptorchidism to generate exposed inci-
denceof cryptorchidism.Althoughpast estimates have identified
prevalence of cryptorchidism ranging from 0.9–1.8% (31), the
panel used a 1% baseline in this analysis. The attributable inci-
dence was then applied against the number of births for each
country in 2010, which was obtained from Eurostat (32).
Modeling phthalate-attributable infertility
The panel selected a longitudinal study (the Longitudinal In-
vestigation of Fertility and the Environment [LIFE] Study) ex-
amining relationships of paternal urinary phthalate metabolites
with time to pregnancy (TTP) as a basis for quantifying couples
seeking ART due to decreased male fertility (33). ART was de-
fined as medically indicated for TTP 12 months, and 56% of
couples with TTP  12 months proceeded to ART in our mod-
eling, based upon data from Boivin et al (34). The population of
women inaconsensualunionbetween theagesof20and44years
in Europe were assumed to have male partners with urinary
phthalate concentrations corresponding to the 10th, 25th, 50th,
75th, and 90th percentiles of adults in theDEMOCOPHESproj-
ect. Data on women in a consensual union were available from
the UnitedNations Department of Economics and Social Affairs
(35) in 25 of the EU countries (except Croatia, Cyprus, and
Luxembourg), and the exposed population in each of the 25
countries was reduced by the percentage of the population using
any contraceptivemethod. The population of 20- to 44-year-old
men was divided into exposure percentile ranges (0-ninth, 10–
24th, 25–49th, 50–74th, 75–89th, and 90–99th). The lowest
exposure grouping was estimated to have no exposure, whereas
the other groups were assumed to have exposure corresponding
to the lowerboundof the range (eg, 10thpercentile for allwomen
in the 10–24th percentile grouping). To calculate the OR for
fecundity in each exposure group, the fecundity OR from the
LIFE Study for monobenzyl phthalate (MBzP) or monobutyl
phthalate (MBP)was exponentiated by the ratio of the estimated
concentration in each exposure group to a reference level of 0.2
ng/mL (the limit of detection typically identified inmost studies).
For example, the 10th percentile was divided by 0.2 and expo-
nentiated by the OR for the LIFE Study to estimate OR of fe-
cundity for the 10–24th exposure percentile of the EU popula-
tion. Recognizing that infertility is not rare and that application
of theORcould lead tooverestimation,weestimated relative risk
from OR using the formula of Zhang and Yu (36).
To translate reduced fecundity into increases in TTP  12
month, data on TTP from aGerman study of 346 natural family
planning couples (mean age of female partner, 29 3.7 y) were
obtained (37). This study measured TTP over a 12-month pe-
riod. We modeled shifts from the TTP in the EU by multiplying
months to conception for each exposure group of the population
by the inverse of the relative risk of infecundity corresponding to
the appropriate level of exposure. The percentage of the popu-
lation shift in TTP due to phthalate exposure above 12 months
was quantified as the incremental prevalence of infertility attrib-
utable to MBzP or MBP. This incremental prevalence was only
applied to 92%of the population, corresponding to the percent-
age who conceived in  12 months in the German study. The
panel determined there to be substantial laboratory evidence for
dose-additive effects of theparent compoundsofMBzPandMBP
and agreed upon addition of the attributable infertility forMBzP
to the attributable infertility forMBP after subtracting the prod-
uct of the two percentages to avoid double counting.
Modeling PBDE-attributable testicular cancer
The expert panel used a case-control study of testis cancer in
relation to the sum of maternal PBDE-47, PBDE-99, and PBDE-
153 in serum (above the median in the controls, 3.66 ng/g lipid).
Using the PBDE-47biomarker estimatedmean and SD in the EU,
the percentages above 3.66 ng/g were estimated using the
NORMDIST function inMicrosoft Excel for base case estimates
and sensitivity analyses. The panel recognized that this approach
would underestimate the attributable cases because the research-
ers in the primary study did not have individual-level data on
each congener. The exposure prevalence above 3.66 ng/g of
PBDE-47 was input into the Levin equation along with the OR
for testicular cancer to calculate the PBDE-attributable fraction.
Sensitivity analyses recalculated the attributable fraction based
upon alternate estimates of biomarkers of the EU, yielding a
different percentage of exposure above 3.66 ng/g. The resultant
attributable fractions were applied against the testis cancer in-
cidence in the EU (38) and population estimates from theWorld
Bank (39) to calculate annual PBDE-attributable cases of testic-
ular cancer in the EU.
Modeling phthalate-attributable decreases in T
The panel used a cross-sectional study of a nationally repre-
sentative US sample in 2011–2012 (40) to quantify decrements
in T in the European population attributable to phthalate expo-
sure among 55- to 64-year-old men. Meeker and Ferguson (40)
identified exposure-response relationships (ERRs) of urinary to-
tal DEHP metabolites and urinary MBP with serum T levels
among 40 to 60 year olds, expressed as a percentage decrement
per unit increase in phthalate metabolite on the basis of the in-
terquartile range in theUSsample.Given that estimatedEU levels
ofMBParemuchhigher than that identified in theUS sample, the
ERR for MBP may not apply in the highest ranges of exposure.
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The ERR was therefore only applied until the 75th percentile
(11.2 g/dL) in the Meeker and Ferguson (40) study. ERRs for
total DEHP metabolites were applied over the entire range of
biomarkers in the EU as estimated from DEMOCOPHES. For
MBP and DEHP metabolites, the 10th percentile was applied as
a reference level. For populations in the 25–49th, 50–74th, 75–
89th, and 90–99th percentiles, decrements in T attributable to
DBP (the MBP parent compound) and DEHP were quantified
and added together to generate decrements in T attributable to
phthalates.
Modeling public health consequences of decreased T
The panel used a meta-analysis of 11 longitudinal studies
(mean age, 61 y; average follow-up, 10 y) that identified in-
creased all-cause mortality (RR 1.35, 95% confidence interval
[CI], 1.13–1.62) in associationswith lowerT levels, expressedon
the basis of a difference between the lowest and highest tertiles
(41). Data from a large, representative European sample (42)
were used to identify an increment in T between the lowest and
highest tertiles (5.10 nmol/L) on which to apply the RR of 1.35
from the meta-analysis. After generating an increase in risk of
mortality per nmol/L decrease in serum T, this was applied
against the decrement in T due to phthalates in each exposed
quantile to generate relative risk of death due to phthalate-at-
tributable decreases in T. Baseline age-standardized mortality
rateswere obtainedbyOrganisation forEconomicCo-operation
and Development from each country (43). Applying these rates
to the estimated relative risk in the presence of reduced T gen-
erated the phthalate-exposed mortality rate, from which the
baseline rate was subtracted to generate the attributable incre-
ment in death rate. This increment in death rate was applied
against population data from the United Nations from each
country (44) to generate the attributable number of annual
deaths among 55 to 64 year olds.
Results
PBDE-attributable cryptorchidism
The panel identified a high-quality case-control study
exploring the association between cryptorchidism and
PBDEconcentrations in breastmilk (62 cryptorchidmales
and 68 controls) and placenta (95 cryptorchid males and
185 controls) (29). Breast milk and placenta concentra-
tions were considered proxies for fetal exposure. Positive
associations were found between breast milk concentra-
tion of PBDEs and cryptorchidism in theDanish and com-
bined Danish-Finnish mother-child pairs, but not in the
Finnish mother-child pairs alone. The overall OR per log
unit increase in PBDE-47 was 5.6 (95% CI, 1.7–18.6)
(45). The Finnish data demonstrated a directionality of
associations similar to the Danish data, but it was not
statistically significant (P  .06). There were no associa-
tions of placental PBDEs with cryptorchidism in either
cohort. Breast milk contains more fat than placental
tissue, and therefore the PBDE concentrations in the
placental tissuewere lower, andmeasurementswere less
certain. Because this was only a single small case-con-
trol study, the panel’s confidence in the effect estimate
is limited, and thus the panel evaluated the strength of
evidence to be low.
There are no developmental animal toxicity studies in-
vestigating whether PBDEs induce cryptorchidism. How-
ever, exposure in adult male rats has shown clear adverse
effects and antiandrogenicity in a Hershberger assay (46).
Also, developmental exposure has been shown to affect
anogenital distance (AGD) and preputial separation in
male pups (47). There are several in vitro studies showing
an antiandrogen mechanism of action (46, 48). Cryp-
torchidism is considered as one of the classical effects of
exposure to antiandrogenic substances duringmale sexual
development (49). The panel therefore identified strong
toxicological evidence for PBDEs as an antiandrogen
causing cryptorchidism in experimental animals. Using
the Intergovernmental Panel on Climate Change (IPCC)
criteria, the sum of the toxicological and epidemiological
evidence suggests 40–69% probability of causation.
Using the range of scenarios for serum PBDE based
upon available data aswell as a range of breastmilk/serum
ratios, the upper median of EU newborns was exposed to
levels ranging from 3.25–7.83 ng/g, with lower (1.78–
4.07 ng/g) and higher (6.02–14.51 ng/g) bound scenarios
Table 1. PBDE-Attributable Cryptorchidism in Europe, 2010
Expert panel evaluation of epidemiological evidence Low
Expert panel evaluation of toxicological evidence Strong
Probability of causation, % 40–69
Percentile of exposure 0–9 10–24 25–49 50–74 75–89 90
Percentile assumed 0 10 25 50 75 90
Estimated breast milk PBDE-47 (base case) LOD LOD LOD 3.25 5.76 7.83
Estimated breast milk PBDE-47 (lower bound) LOD LOD LOD 1.78 2.98 4.07
Estimated breast milk PBDE-47 (higher bound) LOD LOD LOD 6.02 10.66 14.51
Odds of cryptorchidism (base case) 1.00 1.00 1.00 1.00 1.53 1.93
Odds of cryptorchidism (lower bound) 1.00 1.00 1.00 1.00 1.47 1.86
Attributable increment in cryptorchidism 4615 (4155–4615)
Attributable costs of cryptorchidism €130 million (€117–130 million)
Abbreviation: LOD, limit of detection.
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(Table 1). Using the 50th percentile as the reference level,
main estimates identified ORs of 1.53 and 1.93 in the two
most highly exposed groups, comprising one-fourth of the
population, while lower bound estimates identified ORs
of 1.47 and 1.86, respectively. Using these inputs, the
panel estimated 4615 attributable cases (sensitivity anal-
ysis, 4155–4615) with associated costs of €130 million
(sensitivity analysis, €117–130 million).
Phthalate-attributable ART
The panel identified several epidemiological studies ex-
ploring the associations between urinary concentrations
of phthalate metabolites and poorer semen quality, a pre-
dictor of fertility (50). Several publications on men from
infertility clinics founddecreased semenquality in relation
to higher urinary concentrations of phthalate metabolites
(51–53). However, studies among young men from the
general population did not find associations of urinary
concentrations of phthalate metabolites with poorer se-
men quality (54, 55). Differences in the study population
may account for differences in sensitivity to phthalates,
with couples presenting to infertility clinics at increased
risk of poorer semen quality in relation to phthalate ex-
posure. The lack of consistent findings across the studies
dampenedconfidenceof thepanel for thepresenceofdose-
response relationships in the positive studies. Overall, the
panel identified low strength of the epidemiological evi-
dence for phthalate exposure causing reduced semenqual-
ity, thereby contributing to the increased need for ART.
The panel recognized, based on toxicological studies,
that the period of fetal development is more vulnerable to
phthalate and other antiandrogen exposures than adult
exposures. Additional and supportive human data asso-
ciate fetal exposure to phthalates with reduced infant
AGD (56, 57), and shortened adult AGD is associated
with reduced semenquality (58) andT level (59).Tracking
of AGD from infancy to adulthood has not been studied,
however, and so this evidence did not increase confidence
in the degree of causation by the panel.
Lower semen quality has an impact on the TTP and the
ability to have a child (60, 61). In addition to the publi-
cations on phthalates and semen quality, there is recent
additional evidence supporting the association of phtha-
lates with reduced male fertility. Buck Louis et al (33)
studied 505 couples planning a pregnancy and found an
association between higher paternal urinary concentra-
tions of MBP and MBzP and increased TTP, most likely
mediated through altered semen quality. The panel agreed
that this prospective study, well controlled for confound-
ers with an ERR, provided further support for causation,
but the panel also agreed that the study did not have data
on semen quality to suggest a mediation path leading to
increased TTP. The panel therefore assessed low epidemi-
ological evidence supporting causation of adult phthalate
exposure with increased TTP.
In reviewing the toxicological data on phthalate expo-
sure and fertility outcomes, the panel identified extensive
and strong evidence that developmental exposure to sev-
eral antiandrogenic phthalates affectedmale reproductive
development, leading to a long list of adverse effects in-
cluding reduced AGD, increased prevalence of hypospa-
dias and cryptorchidism, reducedT, and lowspermcounts
in adulthood (22, 62, 63). Although the adult male repro-
ductive system is less sensitive to phthalate exposure, in-
sofar as higher doses are required to affect fertility out-
comes (64, 65), the panel agreed that the toxicological
evidence for phthalate-induced infertility is strong.
The LIFE study found associations of MBzP and MBP
with increasedTTPquantifiedby fecundityORs (0.82and
0.77, respectively, in full multivariablemodels) using Cox
proportional hazardmodels (33). The panel suggested us-
ing a reference level of 0.2 ng/mL, the typical level of de-
tection for urinary phthalates in most laboratories.
In each of the exposed groups anticipated to have uri-
nary phthalate concentrations corresponding to the 10th,
25th, 50th, 75th, and 90th percentiles inDEMOCOPHES,
fecundity ORs of 0.68–0.85 were identified for MBzP,
whereasORsof0.52–0.65were identified forMBP(Table
2). Attributable increments in infertility over and above
the baseline of 8% ranged from 2–6% for MBzP and
6–11% for MBP. Attributable increments in infertility
rates across the entire EU population were 3.30 and
7.15%, respectively. After accounting for double count-
ing, the attributable increment in infertilitywas 9.38%. In
the EU, excluding Croatia, Cyprus, and Luxembourg (for
whichnodatawere available), 59.5millionwomen15–49
years of age were identified to be in a consensual union, of
whom 11.8 million were ages 20–44 and not using con-
traception. Applying the attributable increment of 9.38%
and accounting for only 56% of couples seeking medical
care, 618 000 infertility treatments were identified, at a
cost of €4.71 billion. Overall, using the IPCC criteria, the
probability of causation of male infertility by phthalate
exposure was identified to be 40–69%.
PBDE-attributable testis cancer
The panel identified case-control studies in which EDC
levels were measured, three of which measured EDCs in
men with testis cancer compared to control men (66, 67).
However, in some studies the exposurewasmeasured out-
side the relevantperinatalwindow(7, 8), ie, exposure after
birth, and therefore only the study by Hardell et al (67)
was considered further.
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The panel focused on one case-control study associat-
ing maternal levels of PBDEs with testis cancer in their
sons (67). This study assumed that currentmaternal levels
are a proxy for fetal exposure decades in the past. There
wasa statistically significant increasedORof2.5 (95%CI,
1.02 to 6.0) of testis cancer in relation to higher maternal
levels of the sum of PBDE-47, -99, and -153 measured at
the time of diagnosis of testis cancer in cases. One of the
limitations was that maternal exposure was measured de-
cades after pregnancywith the index son (case or control).
The study sample size was small (44 cases and 45 con-
trols). Based on these limitations, our confidence in a sin-
gle study was reduced below the usual low confidence
provided by an observational study, and the panel deter-
mined the level of evidence to be very low.
Although there is no animal model of testis cancer, as
previously described in the context of cryptorchidism, PB-
DEs are antiandrogenic (46). Chemicals that disturb an-
drogen signaling may adversely effect testis development
(46, 68), which in turn may increase the risk of testis can-
cer. Despite substantial plausibility, due to the absence of
an animal model for testis cancer, the panel found weak
experimental evidence for causation by PBDEs.
Using the IPCC criteria, the panel agreed on a proba-
bility of causation between 0 and 19%. Attributable frac-
tions were estimated to range from 13.0–35.3%, with a
base estimate of 35.3% (Table 3). In total, 19 350 annual
cases of testicular cancer were identified, of which 6830
were attributable (range, 2520–6830), with associated
costs of €848 million (range €313 million to 848 million).
Phthalate-attributable reductions in T and
resultant increased mortality (Table 4)
The panel identified 11 manuscripts on the association
of the levels of urinary phthalate metabolites and serum T
in adultmen (40, 51, 54, 55, 69–75). Studies onmen from
infertility clinics were eliminated because T levels may be
lower than in men of the general population of the same
age, limiting their appropriateness for modeling the asso-
ciation of phthalateswithT. Because the focus of the panel
was on the potential association of EDCs with lower T
mediating increased risk of all-cause mortality, the review
Table 2. Phthalate-Attributable Male Infertility and Resulting ART, 2010
Expert panel evaluation of epidemiological evidence Low
Expert panel evaluation of toxicological evidence Strong
Probability of causation, % 40–69
Percentile of exposure 0–9 10–24 25–49 50–74 75–89 90
Percentile assumed 0 10 25 50 75 90
Urinary MBzP, ng/mL 0 1.4 2.5 4.5 8.7 18
MBzP-exposed fecundity OR 1.00 0.85 0.80 0.76 0.72 0.68
Urinary MBP, ng/mL 0 8.9 14.9 24.5 41.4 68
MBP-exposed fecundity OR 1.00 0.65 0.61 0.58 0.55 0.52
Rate of infertility across entire population of
couples attributable to MBzP, %
3.30
Rate of infertility across entire population of
couples attributable to MBP, %
7.15
Total rate of infertility across entire population
attributable to MBP /or MBzP (accounting for
double counting), %
9.38
Women ages 15–49 in consensual union, n 59 527 000
Women ages 20–44 in consenual union not using
contraception, n
11 765 294
Attributable infertility cases seeking medical care, n 618 000
Cost of ART attributable to phthalate exposure €4.71 billion
Table 3. PBDE-Attributable Testicular Cancer in Europe, 2010
Expert panel evaluation of epidemiological evidence Very low
Expert panel evaluation of toxicological evidence Weak
Probability of causation, % 0–19
Exposure prevalence (sensitivity analysis), % 36.4 (10.0, 36.4)
OR 2.5
Attributable fraction (sensitivity analysis), % 35.3 (13.0, 35.3)
Annual incidence 0.0000764
Annual newly incident cases, n 19 349
Attributable cases (sensitivity analysis), n 6830 (2520–6830)
Attributable costs (sensitivity analysis) €848 million (€313–848 million)
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was further limited to studies on men from the general
population by excluding one study on selected fertile men
and two studies in an occupational setting, resulting in
four studies on urinary phthalatemetabolites and serumT
levels in adultmen from the general population. The panel
therefore focused on four studies on urinary phthalate
metabolites and serumT levels in adult men from the gen-
eral population (40, 54, 55, 73).
Three of the studies were of young men (ages 18–40 y)
and did not show inverse association of phthalate expo-
sure with T (54, 55, 73). The only study of older, middle-
aged men from the general population (40–60 y old)
showed negative associations between levels of urinary
phthalates and serum T levels (40). In the Meeker et al
study (40), among the strata of middle-age men (age,
40–60y) therewerenegative associationsof urinary levels
ofMBPand sumofDEHPmetaboliteswith lowerT.There
were significant 12.9% (95%CI,20.3,4.87) and bor-
derline significant decreases of 7.84% (15.8, 0.85) in
serum T with an interquartile range increase in MBP and
DEHP metabolites, respectively.
As described in the discussion of phthalates and male in-
fertility, theperiodof fetaldevelopment ismorevulnerable to
phthalate and other antiandrogen exposures than adult ex-
posures. Additional and supportive human data associate
fetal exposure to phthalates with reduced infant AGD (56,
57), andadultAGDisassociatedwith reducedsemenquality
(58) andT level (59).Yet, the absence of data about tracking
of AGD from infancy to adulthood limited the strength of
epidemiological evidence beyond the low level.
As described in the context of infertility, the toxicolog-
ical data identifying phthalate inhibition of T synthesis is
extensive and strong for developmental exposure in ani-
mal studies (76, 77).Although the adultmale reproductive
system is less sensitive to phthalate exposure (77) and in-
terspecies differences in the impact of DBP on T have been
suggested (77), the panel agreed that the toxicological ev-
idence for phthalate-induced inhibition of T synthesis is
strong for DEHP (78), diisononyl phthalate, butylbenzyl
phthalate, and DBP (79). Using the IPCC criteria, the tox-
icological and epidemiological evidence support a 40–
69% probability of causation.
Exposures to DBP and DEHP were identified to be es-
sentially ubiquitous in the EU population, although as a
conservative measure, we used the 10th percentile (0.040
M forDBP, 0.025M forDEHP) as a reference level,with
levels as high as 0.306 and 0.238 M, respectively, in the
10% most highly exposed portion of adult men. Three-
fourths of the population were estimated to have a 4.07%
reduction in T due to DBP exposure, whereas DEHP-at-
tributable decrements in T were more varied (2.04 to
25.77% decreases). Overall, 1.01 to 4.92 nmol/L decre-
ments in mean T were estimated, with associated relative
risks of mortality ranging from 1.06 to 1.34. In total,
24 820 deaths were attributable to phthalate-attributable
reductions in T, with €7.96 billion in associated lost eco-
nomic productivity.
Discussion
Themajor finding of the present study is that exposures to
specificEDCsacross the life spanare likely to substantially
contribute to male reproductive disorders and diseases in
the EU, with economic costs of approximately €15 billion
annually. Prevention of exposure to PBDEs, and phtha-
lates in particular, is likely to reduce disease, disability,
and even death among European citizens while reducing
health care expenditures and other social costs.
The present analysis was limited to chemical exposures
for which the most substantial epidemiological and toxi-
cological evidence has accumulated to support causation.
There is documented widespread exposure to many other
EDCs, such as bisphenol A, parabens, polyfluorinated
Table 4. Phthalate-Attributable Decreases in T in Europe, 2010
Expert panel evaluation of epidemiological evidence Low
Expert panel evaluation of toxicological evidence Strong
Probability of causation, % 40–69
Percentile of exposure 0–9 10–24 25–49 50–74 75–89 90
Percentile assumed 0 10 25 50 75 90
Urinary MBP, micromolar LOD 0.040 0.067 0.110 0.186 0.306
Urinary DEHP metabolites, micromolar LOD 0.025 0.042 0.076 0.136 0.238
MBP-related change in T (assuming 10th percentile reference level), % 0.00 0.00 4.07 4.07 4.07 4.07
DEHP related changes in T (assuming 10th percentile reference level), % 0.00 0.00 2.04 6.22 13.46 25.77
Change in mean T, nmol/L 0.00 0.00 1.01 1.70 2.89 4.92
Mortality RR (assuming 1.35 RR per 5.10 nmol/L increment in T) 1 1 1.06 1.10 1.19 1.34
Deaths of 55 to 64-y-old men (baseline), n 241 187
Incremental deaths resulting from phthalate-attributable T, n 24 820
Lost economic productivity €7.96 billion
Abbreviation: LOD, limit of detection.
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chemicals, and newer flame retardants (eg, Firemaster
550) (40, 80–83). However, due to the lack of sufficient
epidemiological studies at this time, the panel was unable
to consider these in its deliberations.Thepanelwas limited
by the absence of epidemiological studies linking fetal ex-
posures with later life conditions such as infertility that
arise 30 or more years later. Absent such data, the panel
was unable to assert with certainty estimates of disease
burden due to earliest life exposure, and instead focused
onquantifying attributable disease to adult exposure. Fur-
thermore, the panel did not consider cumulative exposure
to multiple EDCs that may act additively to adversely im-
pact androgenic signaling that disrupts human male re-
productive tract development and adversely affects male
reproductive health (84).
The panel acknowledged the possibility of reverse cau-
sation between low T and cardiovascular disease and rec-
ognized the presence of two studies suggesting adverse
cardiovascular effects of T replacement therapy in older
men (85, 86),whichmight argue against the implicationof
mortality and lost economic productivity due to phtha-
late-attributable reductions in T. The panel noted that the
Vigen et al study (85) was retrospective, based on registry
data, and lacked information about cumulative dose. The
Basaria et al study (86) administered rather high doses of
T, for which the platelet aggregation effects and smooth
muscleproliferationcouldhaveoutweighed thebenefits of
compensating for lower endogenousproduction.Multiple
observational studies have suggested that reduced endog-
enous production of T is associated with increased risk of
mortality, chiefly due to cardiovascular events (41). We
also note the potential overlap of phthalates-attributable
mortality in men with phthalate-attributable obesity and
diabetes, despite control in studies of T and mortality for
body mass index. The obesity and diabetes panel (87) did
not attribute obesity and diabetes to phthalate exposures
in men due to lack of epidemiological studies in that sub-
population, and so double counting is not a concern.
The panel could have also included cost estimates of
osteoporotic fractures as downstreameffects of phthalate-
attributable lower T, although the association between T
and osteoporosis is influenced by aromatase activity (88)
and thereby estradiol levels. T is a precursor to estradiol,
which ismorepredominant in its effects onbone, although
T may also have direct effects (89). Given the uncertainty
of the influence of phthalates on the T-estrogen axis, the
panel decided not tomodel osteoporotic fractures as costs
of phthalate-induced effects.
Most studies of phthalate exposures have examined T,
whereas emerging research suggests that the ratio of T to
LH, dihydrotestosterone, and other biomarkers may be
more reflective of androgen disruption and more directly
in the causal pathwayofmale reproductive conditions due
to EDCs. As this domain of research evolves, the estima-
tion of EDC-attributable male reproductive morbidities
may evolve to account for these biomarkers.
Major strengths of our approach include the transpar-
ent use of available data to define exposure-related out-
comes and the distribution of exposures in EU countries,
and such estimates will become more precise as better ev-
idence becomes available. The causal attribution is sup-
ported by experimental data, and judgment in regard to
reference levels, impact of covariates, and steepness of the
dose-dependence of the outcomeswas based on consensus
among the authors. Likewise, biomarker data were not
available for all EU countries, and judgment was used in
extrapolating to the EU as a whole. By this approach, the
authors attempted to avoid underestimating the burden of
disease simply because of insufficient or lacking data (90).
On the other hand, the calculations could not take into
account potential differences between exposure levels in
the member states.
Having raised appropriate caveats, the present study
suggests substantial economic benefits to prevention of
EDCexposure,which should be placed alongside the costs
of developing safer alternatives. The burden of male re-
productive morbidity attributable to PBDE is likely to be
even more substantial in the United States, where expo-
sures remain substantially higher. In contrast, the burden
attributable to phthalates may be more modest in the
United States (where data from national surveys suggest
lower levels of MBP and DEHP metabolites) (91) com-
pared to the EU.This speaks to the substantial influence of
regulatory policy on humanhealth and disease and should
inform thoughtful and proactive prevention of environ-
mental hazards.
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